SCHEMBL4097178

SCHEMBL4097178

O=C(COc1ccc(Cl)cc1)Nc1cccc(C(=O)Nc2ccccc2C(=O)O)c1

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 6/20 0.60
MEN1 O00255 5/20 0.60
HIF1A Q16665 3/20 0.59
EPAS1 Q99814 3/20 0.59
SUCNR1 Q9BXA5 1/20 0.59
NPC1 O15118 2/20 0.58
RAB9A P51151 2/20 0.58
SENP8 Q96LD8 2/20 0.57
SENP7 Q9BQF6 2/20 0.57
SENP6 Q9GZR1 2/20 0.57
POLB P06746 2/20 0.57
MAPT P10636 1/20 0.57
KCNH2 Q12809 1/20 0.56
CYP1A2 P05177 1/20 0.56
CYP2D6 P10635 1/20 0.56
CYP2C9 P11712 1/20 0.56
CYP2C19 P33261 1/20 0.56
HCAR2 Q8TDS4 1/20 0.56
PKM P14618 1/20 0.55
CASP3 P42574 1/20 0.55

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13870846 0.90 HCAR2 (0.71) KMT2AMEN1HIF1AEPAS1NPC1
SCHEMBL4096488 0.87 MEN1 (0.64) KMT2AMEN1SUCNR1NPC1RAB9A
SCHEMBL13870829 0.86 KMT2A (0.67) KMT2AMEN1HIF1AEPAS1NPC1
SCHEMBL2947489 0.84 MEN1 (0.78) KMT2AMEN1HIF1AEPAS1NPC1
SCHEMBL4912964 0.84 NPC1 (0.80) KMT2AMEN1HIF1AEPAS1NPC1
SCHEMBL4092498 0.81 KMT2A (0.60) KMT2AMEN1SUCNR1NPC1RAB9A
SCHEMBL26808959 0.80 KMT2A (0.80) KMT2AMEN1NPC1RAB9AMAPT
SCHEMBL26808978 0.80 KCNK3 (0.70) KMT2AMEN1SUCNR1NPC1RAB9A
SCHEMBL26670365 0.80 POLB (0.73) KMT2AMEN1SUCNR1NPC1RAB9A
SCHEMBL4301497 0.79 KCNH2 (0.61) KMT2AMEN1HIF1AEPAS1POLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090105218-A1 CRTH2 Receptor Ligands For Therapeutic Use 7TM PHARMA A/S (DK) 2009-04-23 US disclosed
US-20090105218-A1 CRTH2 Receptor Ligands For Therapeutic Use 7TM PHARMA A/S (DK) 2009-04-23 US disclosed
US-20090105218-A1 CRTH2 Receptor Ligands For Therapeutic Use 7TM PHARMA A/S (DK) 2009-04-23 US disclosed
EP-1758571-A1 CRTH2 RECEPTOR LIGANDS FOR THERAPEUTIC USE 7TM Pharma A/S (DK) 2007-03-07 EP disclosed
WO-2005115374-A1 CRTH2 RECEPTOR LIGANDS FOR THERAPEUTIC USE 7TM PHARMA A/S (DK) 2005-12-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090105218-A1 CRTH2 Receptor Ligands For Therapeutic Use NR1H2, NR1H3, HRH2 KMT2A 2570/4885MEN1 2859/4885HIF1A 401/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.